| P/E (FY) | — | Sales (TTM) | SEK 0 |
| Earnings (TTM) | -SEK 285.5M | ROE | −43.38% |
| Net Margin | — | ROIC | −43.69% |
| Debt / Equity | 0.15 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Xspray Pharma AB is a pharmaceutical company in Sweden developing protein kinase inhibitors for targeted cancer treatments. Its pipeline includes Dasynoc, an amorphous form of dasatinib for chronic myeloid leukemia and acute lymphoblastic leukemia, plus XS003 (nilotinib) for CML, XS008 (axitinib) for kidney cancer, and XS025 (cabozantinib) for renal cell carcinoma and other cancers, with a commercialization partnership with EVERSANA for Dasynoc. Formerly Xspray Microparticles AB until its 2017 rename, the company was incorporated in 2003 and is headquartered in Solna, Sweden.
| Market Cap | $55.3M | Trading Days | 2161 |
| 52W High | 64.10 |
| 52W Low | 14.16 |
| % Off High | −74.66% |
| YTD | −48.36% | 1Y | −68.65% |
| 3Y | −46.40% | 5Y | −86.25% |
| Since incept. (ann.) | −7.20% |
| Ann. Volatility (1Y) | 90.20% | Ann. Volatility (3Y) | 80.94% |
| Sharpe (1Y) | −0.74 | Sharpe (3Y) | 0.18 |
| Max Drawdown (1Y) | −76.91% | Max Drawdown (3Y) | −83.42% |
| Beta (3Y, vs SPY) | 0.22 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| DRIO | DarioHealth Corp. | $54.8M | 0.7 |
| SNWV | SANUWAVE Health, Inc. | $54.7M | 4.6 |
| CRDF | Cardiff Oncology, Inc. | $55.9M | — |
| ELTX | Elicio Therapeutics, Inc. | $56.3M | — |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M | — |
| BACTI-B.ST | Bactiguard Holding AB | $57.1M | — |
| MRAI | Marpai, Inc. | $53.1M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M |
| — |
| SCLX | Scilex Holding Co | $57.9M | — |
